Therapy News and Research

RSS

Neoantigen vaccine sparks powerful immune defense against kidney cancer

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to long-lasting T cell expansion and no disease recurrence after 40 months.

6 Feb 2025

RUFY1-RET fusion identified as mechanism of resistance to lorlatinib in lung cancer

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report."

6 Feb 2025

Early adversity in firstborns linked to 71% higher risk of mental health issues in younger sibling

Study reveals firstborns facing adversity increase mental health risks in siblings, highlighting the importance of early intervention and family-based support.

6 Feb 2025

SAB BIO announces positive topline Phase 1 clinical results with potentially disease-modifying T1D therapy SAB-142

SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced positive topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers.

From SAb Biotherapeutics, Inc. 6 Feb 2025

Jumbo phages' protective shield offers clues for fighting antibiotic resistance

Scientists are learning more about how an intriguing type of virus protects itself. Revealing its strategies could boost the fight against antibiotic resistance.

6 Feb 2025

Depression linked to specific changes in eating preferences

Depression affects 280 million people worldwide. The mental illness has been proven to lead to changes in eating behavior.

6 Feb 2025

MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition of SeQure Dx, a market leader of on-target and off-target editing assessment services for cell and gene therapies.

From MaxCyte, Inc. 6 Feb 2025

Research disproves persister bacteria as main cause of antibiotic resistance

Antibiotics are indispensable for treating bacterial infections. But why are they sometimes ineffective, even when the bacteria are not resistant? In their latest study published in the journal Nature, researchers from the University of Basel challenge the conventional view that a small subset of particularly resilient bacteria are responsible for the failure of antibiotic therapies.

5 Feb 2025

Inhibiting S6K2 gene offers potential treatment for drug-resistant melanoma

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .

5 Feb 2025

No extra benefit from mechanical clot removal over medications in some strokes

Removing a clot blocking a medium- or small-sized artery in the brain mechanically is a safe treatment for a common type of stroke; however, it did not lessen disability more than best medical treatment (including clot-busting medication if indicated) alone, according to preliminary late-breaking science presented today at the American Stroke Association's International Stroke Conference 2025.

5 Feb 2025

Neurostimulation improves movement in adults with spinal muscle atrophy

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.

5 Feb 2025

Can cognitive-behavioral therapy components be tailored to optimize ADHD treatment?

A meta-analysis of 43 trials identifies key CBT components, including third-wave therapy and organizational strategies, as effective for managing ADHD symptoms.

5 Feb 2025

Scientists design strategy for preventing cardiotoxic effects of anthracyclines

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic effects of anthracyclines, a widely used class of anticancer drugs.

4 Feb 2025

Microbes in your gut could determine cancer treatment outcomes

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment, with specific bacterial strains enhancing or inhibiting anti-tumor immunity.

4 Feb 2025

International trial aims to prevent Alzheimer’s in high-risk young adults

The first participants in an international clinical trial aimed at preventing Alzheimer's disease in young adults at high risk of the disease have been enrolled.

4 Feb 2025

Study identifies most effective CBT components for treating ADHD

Attention-deficit hyperactivity disorder (ADHD) is a well-known neurodevelopmental disorder that affects the brain's ability to regulate attention and control impulses.

4 Feb 2025

Breakthrough drug improves treatment of medulloblastoma in mice

Brain cancer is the second-leading cause of death in children in the developed world. For the children who survive, standard treatments have long-term impacts on their development and quality of life, particularly in small children and infants.

4 Feb 2025

Yo-yo dieting found to harm kidney health in type 1 diabetes patients

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI) and other traditional risk factors, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

4 Feb 2025

High discontinuation rates of GLP-1 agonists found among patients with obesity

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting treatment effectiveness.

4 Feb 2025

Engineered fat cells starve tumors and prevent cancer growth

Scientists transformed energy-storing white fat cells into calorie-burning 'beige' fat. Once implanted, they outcompeted tumors for resources, beating back five different types of cancer in lab experiments.

4 Feb 2025